Development of the Novel Therapeutic Strategy for Cerebral Infarction; The Efficacy of Angiotensin II DNA Vaccine in Rat Model of Cerebral Infarction.
Project/Area Number |
24791487
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Cerebral neurosurgery
|
Research Institution | The University of Tokyo |
Principal Investigator |
KOUJI Wakayama 東京大学, 医学部附属病院, 助教 (50349263)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | 脳血管障害 / ワクチン療法 / 脳梗塞 / ワクチン / 非感染性疾患 / 予防的治療 / 脳神経外科 |
Outline of Final Research Achievements |
The feasibility of therapeutic application of angiotensin II (Ang II) DNA vaccine against middle cerebral artery occlusion (MCAo) in rat was investigated. Because of its low immunogenicity of Ang II DNA vaccine, the level of serum Ang II titer remained extremely low. The application of Ang II peptide vaccine was investigated to solve this problem. Ang II peptide vaccine induced substantially high level of Ang II titer in sera, which motivate us to verify the cerebroprotective effects of Ang II peptide vaccine against MCAo rat. The findings indicated that efficacy of Ang II peptide vaccine including amelioration of ischemic brain damage and neurological dysfunction was exerted only when sufficient level of serum Ang II titer was obtained at the time of cerebral ischemic insult. The antioxidative effect through inhibitory effect against brain rennin angiotensin system was the suggested mechanism of Ang II peptide vaccine in cerebral ischemia.
|
Report
(4 results)
Research Products
(1 results)